73 results
10-K
2022 FY
OBSVF
ObsEva SA
31 Mar 23
Annual report
4:01pm
to support their research and development efforts, conduct testing and clinical trials, obtain regulatory approvals to market products, manufacture … competition from smaller companies who, like us, rely on investors to fund research and development and compete for co-development and licensing
6-K
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
product candidates, we could be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio expansion
6-K
EX-99.1
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
Assignment income
Total operating income other than revenue
OPERATING EXPENSES
Research and development expenses
General and administrative expenses … or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its
6-K
EX-99.2
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
and the assignment of contractual obligations.
Operating Expenses
Research and Development Expenses
Research and development expenses consist primarily … of costs incurred in connection with our research and development activities and consist mainly of direct research and development costs, which include
6-K
EX-99.3
OBSVF
ObsEva SA
1 Dec 22
Index to Unaudited Condensed Consolidated Financial Statements
4:15pm
assignment of linzagolix contracts.
Research and development expenses were approximately $0.7 million for the quarter ended September 30, 2022 …
Total operating income other than revenue
OPERATING EXPENSES
Research and development expenses
General and administrative expenses
Impairment
6-K/A
EX-99.1
9grhz8v
13 Sep 22
Index to Unaudited Condensed Consolidated Financial Statements
9:08am
6-K
EX-99.1
41s5a9fcab
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.2
nwk 047npydm23
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
47p aevgax8j
17 Aug 22
Index to Unaudited Condensed Consolidated Financial Statements
4:01pm
6-K
EX-99.3
j8wh16g3e ve
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
j54rxedw4hmp70q
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
6wk k1pgul
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.2
wyn96ny9999y0 1d
17 May 22
Index to Unaudited Condensed Consolidated Financial Statements
7:00am
6-K
EX-99.1
pmle9q2ciao7
10 Mar 22
ObsEva Announces Year End 2021 Financial Results and Provides Corporate Update
7:11am
424B7
z6c1m4vzpd224c
3 Mar 22
Prospectus with selling stockholder info
4:43pm
F-3
qgo 5cd01txkz
17 Feb 22
Shelf registration (foreign)
4:14pm
424B7
1lh7rin u0hl9lf2yza
23 Nov 21
Prospectus with selling stockholder info
4:06pm